Flomoxef
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Flomoxef
- DrugBank Accession Number
- DB11935
- Background
Flomoxef has been used in trials studying the treatment of Urinary Tract Infection.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 496.46
Monoisotopic: 496.064645618 - Chemical Formula
- C15H18F2N6O7S2
- Synonyms
- Flomoxef
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir Flomoxef may decrease the excretion rate of Abacavir which could result in a higher serum level. Abciximab The therapeutic efficacy of Abciximab can be decreased when used in combination with Flomoxef. Aceclofenac The risk or severity of nephrotoxicity can be increased when Aceclofenac is combined with Flomoxef. Acemetacin The risk or severity of nephrotoxicity can be increased when Flomoxef is combined with Acemetacin. Acenocoumarol The risk or severity of bleeding can be increased when Flomoxef is combined with Acenocoumarol. - Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Product Ingredients
Ingredient UNII CAS InChI Key Flomoxef Sodium 445HIB8XNF 92823-03-5 PPPZBOLFWGINKN-YLCXCWDSSA-M
Categories
- ATC Codes
- J01DC14 — Flomoxef
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as n-acyl-alpha amino acids and derivatives. These are compounds containing an alpha amino acid (or a derivative thereof) which bears an acyl group at its terminal nitrogen atom.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- N-acyl-alpha amino acids and derivatives
- Alternative Parents
- Oxacephems / Alkylarylthioethers / Tetrazoles / Tertiary carboxylic acid amides / Heteroaromatic compounds / Secondary carboxylic acid amides / Azetidines / Alkanolamines / Sulfenyl compounds / Azacyclic compounds show 11 more
- Substituents
- Alcohol / Alkanolamine / Alkyl fluoride / Alkyl halide / Alkylarylthioether / Aromatic heteropolycyclic compound / Aryl thioether / Azacycle / Azetidine / Azole show 28 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- V9E5U5XF42
- CAS number
- 99665-00-6
- InChI Key
- UHRBTBZOWWGKMK-DOMZBBRYSA-N
- InChI
- InChI=1S/C15H18F2N6O7S2/c1-29-15(18-8(25)6-31-13(16)17)11(28)23-9(10(26)27)7(4-30-12(15)23)5-32-14-19-20-21-22(14)2-3-24/h12-13,24H,2-6H2,1H3,(H,18,25)(H,26,27)/t12-,15+/m1/s1
- IUPAC Name
- (6R,7R)-7-{2-[(difluoromethyl)sulfanyl]acetamido}-3-({[1-(2-hydroxyethyl)-1H-1,2,3,4-tetrazol-5-yl]sulfanyl}methyl)-7-methoxy-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
- SMILES
- CO[C@]1(NC(=O)CSC(F)F)[C@H]2OCC(CSC3=NN=NN3CCO)=C(N2C1=O)C(O)=O
References
- General References
- Not Available
- External Links
- PubChem Compound
- 65864
- PubChem Substance
- 347828262
- ChemSpider
- 59274
- ChEBI
- 135813
- ChEMBL
- CHEMBL15413
- ZINC
- ZINC000003874302
- Wikipedia
- Flomoxef
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data3 Terminated Treatment Urinary Tract Infection 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 1.22 mg/mL ALOGPS logP -0.59 ALOGPS logP -0.11 Chemaxon logS -2.6 ALOGPS pKa (Strongest Acidic) 3.28 Chemaxon pKa (Strongest Basic) -1.5 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 10 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 169 Å2 Chemaxon Rotatable Bond Count 11 Chemaxon Refractivity 119.66 m3·mol-1 Chemaxon Polarizability 43.37 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-07f4-3405900000-6ea4716e9737eab3ff17 Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-0002-0000900000-3db578b4413cf71fbee4 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-0f6t-0000900000-0c2633cc317413a1d41c Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-0w39-8907200000-af8ee8e233c57e88f451 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0229-1319700000-a591d2d165abf235dbae Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-0a4r-9111100000-2ac1ebcada163722a778 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 219.9931849 predictedDarkChem Lite v0.1.0 [M-H]- 202.96071 predictedDeepCCS 1.0 (2019) [M+H]+ 220.4911849 predictedDarkChem Lite v0.1.0 [M+H]+ 205.31871 predictedDeepCCS 1.0 (2019) [M+Na]+ 220.3911849 predictedDarkChem Lite v0.1.0 [M+Na]+ 211.41185 predictedDeepCCS 1.0 (2019)
Drug created at October 20, 2016 21:02 / Updated at February 21, 2021 18:53